PCBP1 and urinary bladder carcinoma: To further validate the immunotherapy effect of PCBP1-AS1, we applied immunotherapy cohorts for three different cancer types (IMvigor210 bladder cancer, GSE78220 melanoma, and GSE135222 NSCLC).